tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cardiomyopathy, Restrictive D002313 1 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Priapism D011317 1 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Knoop C et al. FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: report on five cases. 1994 Transplant. Proc. pmid:7527957
Candinas D et al. Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. 1994 Transplant. Proc. pmid:7527959
Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group. 1994 Transplant. Proc. pmid:7527960
Neuhaus PJ Optimised first-line FK506-based protocols in liver transplantation: experience from the University Hospital Rudolf Virchow, Berlin. 1994 Transplant. Proc. pmid:7527961
Kato H et al. Spontaneous proliferation of peripheral blood mononuclear cells as an indicator for insufficient plasma levels of FK 506 in the early phase after liver transplantation. 1994 Transplant. Proc. pmid:7513481
Sewing KF Pharmacokinetics, dosing principles, and blood level monitoring of FK506. 1994 Transplant. Proc. pmid:7527962
Nishikawa K et al. Experimental studies of vascularized joint allografts in rats. 1994 Transplant. Proc. pmid:7513482
Frei U and Wagner K Renal function in liver transplant patients receiving FK506 or cyclosporin A immunosuppressive therapy. 1994 Transplant. Proc. pmid:7527963
Fukuzawa M and Okada A Analysis of mouse xenogeneic T-cell responses and the effect of FK 506 on these responses and on xeno-skin graft rejection. 1994 Transplant. Proc. pmid:7513483
Morris R Modes of action of FK506, cyclosporin A, and rapamycin. 1994 Transplant. Proc. pmid:7527964
Petuch BR et al. Microbial transformation of immunosuppressive compounds. III. Glucosylation of immunomycin (FR 900520) and FK 506 by Bacillus subtilis ATCC 55060. 1994 J. Ind. Microbiol. pmid:7513528
Shaeffer MS et al. Interaction between FK506 and erythromycin. 1994 Ann Pharmacother pmid:7513563
Lhöest GJ et al. 15-Desmethyl FK-506 and 15,31-desmethyl FK-506 from human liver microsomes: isolation, identification (by fast atom bombardment mass spectrometry and NMR), and evaluation of in vitro immunosuppressive activity. 1994 Clin. Chem. pmid:7513627
Ueda H et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. 1994 J. Antibiot. pmid:7513682
Tai J et al. Effect of FK506 on rat Leydig cell function--in vivo and in vitro study. 1994 Metab. Clin. Exp. pmid:7513780
Cardenas ME et al. Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. 1994 EMBO J. pmid:7529175
Burkhalter EL et al. Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. 1994 J. Hepatol. pmid:7529272
Kawano K et al. Evidence that FK506 alleviates ischemia/reperfusion injury to the rat liver: in vivo demonstration for suppression of TNF-a production in response to endotoxemia. 1994 Eur Surg Res pmid:7516291
Morozumi K and Takeda A [Kidney disorders induced by immunosuppressive agents]. 1994 Nippon Naika Gakkai Zasshi pmid:7529294
Hashimoto T et al. Treatment with FK506 prevents rejection of rat colon allografts. 1994 Transplantation pmid:7516586
Alamartine E et al. In-vitro effects of cyclosporin A, FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells. 1994 Nephrol. Dial. Transplant. pmid:7529381
Konishi M et al. Effects of FK506 on surface antigen expression by regenerating thymocytes after sublethal irradiation in the rat. 1994 Thymus pmid:7532330
Krentz AJ et al. Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of cyclosporine versus FK506. 1994 Transplantation pmid:7516590
Shapiro R et al. A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. 1994 Clin Transplant pmid:7532475
Ludwig B et al. Characterization of Mip proteins of Legionella pneumophila. 1994 FEMS Microbiol. Lett. pmid:7516906
Atcherson MM and Trifillis AL Cytotoxic effects of FK506 on human renal proximal tubule cells in culture. 1994 In Vitro Cell. Dev. Biol. Anim. pmid:7529625
Murthy JN et al. Identification of a 14 kDa FK-506/rapamycin binding immunophilin from calf thymus. 1994 Clin. Biochem. pmid:7532556
Maruyama K et al. FK 506 for vascular permeability factor production in minimal change nephrotic syndrome. 1994 Nephron pmid:7517020
Donnelly JG and Soldin SJ Partial characterization of a 52 kDa CsA/FK506/rapamycin binding protein. 1994 Clin. Biochem. pmid:7532557
High KP The antimicrobial activities of cyclosporine, FK506, and rapamycin. 1994 Transplantation pmid:7517076
Yoshimura N et al. The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. 1994 Transplantation pmid:7517078
Reyes J et al. Lymphoproliferative disease after intestinal transplantation under primary FK 506 immunosuppression. 1994 Transplant. Proc. pmid:7518137
Murase N et al. Small bowel transplantation in sensitized recipients: comparison with heart, kidney, and liver grafts. 1994 Transplant. Proc. pmid:7518139
Fujisaki S et al. Effects of preformed antibodies induced by whole blood transfusion on small bowel transplantation. 1994 Transplant. Proc. pmid:7518140
Spada M et al. Monitoring of intestinal myoelectrical activity after isolated small bowel transplantation in FK 506 immunosuppressed pigs. 1994 Transplant. Proc. pmid:7518141
Spada M et al. Morphology of acute rejection and observation of lymphoproliferative hyperplastic reaction in FK 506 treated pigs after small bowel transplantation. 1994 Transplant. Proc. pmid:7518142
Vischi S et al. The maltose absorption test does not predict allograft rejection of small bowel transplantation in FK 506 immunosuppressed pigs. 1994 Transplant. Proc. pmid:7518143
Okamoto M et al. Detection of allograft rejection in rat small bowel transplantation by analysing the in situ distribution of S-phase lymphocytes. 1994 Transplant. Proc. pmid:7518145
Ippoliti G et al. Serum cytokine levels after small bowel transplantation in pigs. 1994 Transplant. Proc. pmid:7518146
Cakaloglu Y et al. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. 1994 Hepatology pmid:7519161
Luan S et al. Light-regulated, tissue-specific immunophilins in a higher plant. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7508125
Blazar BR et al. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation. 1994 J. Immunol. pmid:7519216
Laifer SA et al. Pregnancy after cardiac transplantation. 1994 Am J Perinatol pmid:7519426
Yoshikawa N et al. Effect of FK-506 on xenografted human Graves' thyroid tissue is severe combined immunodeficient mice. 1994 Clin. Endocrinol. (Oxf) pmid:7519528
Porayko MK et al. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. 1994 Mayo Clin. Proc. pmid:7508536
Kao PN et al. Cloning and expression of cyclosporin A- and FK506-sensitive nuclear factor of activated T-cells: NF45 and NF90. 1994 J. Biol. Chem. pmid:7519613
Jindal RM et al. Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7519799
Mor E et al. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. 1994 Transplantation pmid:7519800
Masaoka T Problems of bone marrow transplantation in Japan. 1994 Transplant. Proc. pmid:7520634
Okano K et al. Ameliorative effect of FK 506 on cold ischemia reperfusion injury of the rat liver. 1994 Transplant. Proc. pmid:7520635
Connelly PR et al. Enthalpy of hydrogen bond formation in a protein-ligand binding reaction. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7510408
Kim YI et al. FK 506 prevents critical warm ischemia damage to the pig liver and improves hepatic microcirculation. 1994 Transplant. Proc. pmid:7520636
Shiraga T et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. 1994 Biochem. Pharmacol. pmid:7510480
Hirai T et al. A short course of FK506 can induce limited donor-specific graft acceptance. 1994 Ann. Thorac. Surg. pmid:7520685
Kuwano K and Arai S The inhibitory effect of FK506 on cytotoxic T-lymphocyte killing. 1994 Immunol. Lett. pmid:7536706
Hossain M et al. Effects of various drugs (staurosporine, herbimycin A, ketotifen, theophylline, FK506 and cyclosporin A) on eosinophil viability. 1994 Arerugi pmid:7520689
Bell A et al. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin. 1994 Biochem. Pharmacol. pmid:7520696
Paslaru L et al. GRP78 induction by cyclosporin A in human HeLa cells. 1994 FEBS Lett. pmid:7520875
Okamoto S et al. The interleukin-8 AP-1 and kappa B-like sites are genetic end targets of FK506-sensitive pathway accompanied by calcium mobilization. 1994 J. Biol. Chem. pmid:7510691
Metcalfe S et al. FK506 and cyclosporin A each inhibit antigen-specific signaling in the T cell line 171 in the absence of a calcium signal. 1994 Cell. Immunol. pmid:7522130
Nichols RA et al. Calcineurin-mediated protein dephosphorylation in brain nerve terminals regulates the release of glutamate. 1994 J. Biol. Chem. pmid:7522234
Nakagawa H et al. Tacrolimus ointment for atopic dermatitis. 1994 Lancet pmid:7522297
Sharkey J and Butcher SP Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. 1994 Nature pmid:7522303
Bram RJ and Crabtree GR Calcium signalling in T cells stimulated by a cyclophilin B-binding protein. 1994 Nature pmid:7522304
Tanaka A et al. Living related liver transplantation across ABO blood groups. 1994 Transplantation pmid:7522363
Devlin J et al. Nitric oxide generation. A predictive parameter of acute allograft rejection. 1994 Transplantation pmid:7522365
Ueda K et al. Human P-glycoprotein as a multi-drug transporter analyzed by using transepithelial transport system. 1994 Jpn. J. Physiol. pmid:7538609
Schleuning M et al. Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives. 1994 Naunyn Schmiedebergs Arch. Pharmacol. pmid:7523957
Perotti BY et al. HPLC assay for FK 506 and two metabolites in isolated rat hepatocytes and rat liver microsomes. 1994 Pharm. Res. pmid:7524055
FDA approved new drug bulletin: aprotinin injection (trasylol), tacrolimus (prograf). 1994 RN pmid:7524131
Apanay DC et al. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. 1994 Transplantation pmid:7524202
Steinmüller TM et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. 1994 Transplantation pmid:7524203
Singh N et al. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. 1994 Transplantation pmid:7524204
Takahara S et al. Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients. 1994 Transplant. Proc. pmid:7524219
Heitman J et al. Antifungal effects of cyclosporine and FK 506 are mediated via immunophilin-dependent calcineurin inhibition. 1994 Transplant. Proc. pmid:7524220
Radanyi C et al. The ability of the immunophilin FKBP59-HBI to interact with the 90-kDa heat shock protein is encoded by its tetratricopeptide repeat domain. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7526392
Abu-Elmagd K et al. Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. 1994 Clin Transpl pmid:7547533
Ko S et al. The pharmacokinetic benefits of newly developed liposome-incorporated FK506. 1994 Transplantation pmid:7526494
Shapiro R et al. Renal transplantation at the University of Pittsburgh: the impact of FK506. 1994 Clin Transpl pmid:7547544
Holländer GA et al. Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. 1994 Transplantation pmid:7526495
Ishioka M et al. FK506 treatment of noninfectious uveitis. 1994 Am. J. Ophthalmol. pmid:7526689
Carroll PB et al. Effect of tacrolimus (FK506) in dystrophic epidermolysis bullosa: rationale and preliminary results. 1994 Arch Dermatol pmid:7526802
Iwata H et al. Suppression of allograft responses by combining alloantigen-specific i.v. pre-sensitization with suboptimal doses of rapamycin. 1994 Int. Immunol. pmid:7511931
Lauerma AI et al. Topical FK506: suppression of allergic and irritant contact dermatitis in the guinea pig. 1994 Arch. Dermatol. Res. pmid:7526805
Mayrleitner M et al. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506 binding protein: effect of FKBP-12 on single channel activity of the skeletal muscle ryanodine receptor. 1994 Cell Calcium pmid:7511990
Bush KT et al. Induction of the FK506-binding protein, FKBP13, under conditions which misfold proteins in the endoplasmic reticulum. 1994 Biochem. J. pmid:7526846
Kahan BD New immunosuppressive drugs--pharmacologic approaches to alter immunoregulation. 1994 Ther Immunol pmid:7584478
Hamajima E et al. Effects of FK506, an immunosuppressive agent, on genesis of water-immersion stress-induced gastric lesions in rats. 1994 Dig. Dis. Sci. pmid:7512015
Akamine S et al. Monitoring canine lung allograft rejection using Ia antigen expression by bronchoalveolar lymphocytes. 1994 Surg. Today pmid:7526914
Tsuchida M et al. The effects of FK506 and dexamethasone on rat thymocyte differentiation. 1994 Ther Immunol pmid:7584489
Matsumoto T et al. Preventive effect of immunosuppressive agents against indomethacin-induced small intestinal ulcers in rats. 1994 Dig. Dis. Sci. pmid:7512017
Todo S et al. Small intestinal transplantation in humans with or without the colon. 1994 Transplantation pmid:7512291
Griffith BP et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. 1994 Transplantation pmid:7512292
Moutabarrik A et al. Effect of immunosuppressive agents FK 506 and cyclosporin and steroids on the expression of IL-6 and its receptor by stimulated lymphocytes and monocytes. 1994 Transpl. Int. pmid:11271305
Winkler M et al. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation. 1994 Transpl. Int. pmid:11271312
Devlin J et al. FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure. European FK 506 Study Liver Group. 1994 Transpl. Int. pmid:11271328
Otto G et al. Corticosteroids and concomitant medication in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation. 1994 Transpl. Int. pmid:11271338
Wong P et al. FK 506 rescue therapy for intractable liver allograft rejection. 1994 Transpl. Int. pmid:11271339
Mor E et al. Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK 506. 1994 Transpl. Int. pmid:11271340
Uemoto S et al. Long-term use of FK 506 in living related liver transplantation. 1994 Transpl. Int. pmid:11271341